Posted by Michael Wonder on 20 Nov 2020
PTC Therapeutics announces key regulatory designations for PTC596 to advance treatment of two rare oncology indications
18 November 2020 - PTC Therapeutics today announced that the United States FDA has granted PTC596 both orphan drug designation and fast track designation for the potential treatment of leiomyosarcoma, a rare type of cancer that affects smooth muscle tissue.
Furthermore, the FDA has also granted PTC596 a rare paediatric disease designation and orphan drug designation for the potential treatment of diffuse intrinsic pontine glioma, an ultra-rare childhood glioma.
